LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of June 4, 2026, LXRX stock price climbed to $1.90 with 1,655,578 million shares trading.

LXRX has a beta of 0.94, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.02 to the broad based SPY ETF.

LXRX has a market cap of $843.79 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $1 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.04.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, SCHA, VHT, PRFZ.

LXRX has outperformed the market in the last year with a return of +187.4%, while the SPY ETF gained +28.3%. In the last 3 month period, LXRX beat the market returning +16.6%, while SPY returned +10.8%. However, in the most recent 2 weeks LXRX has underperformed the stock market by returning -14.8%, while SPY returned +1.9%.

LXRX support price is $1.76 and resistance is $1.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.